Table 2 CDE biomolecules in the TME
Cancer type | Biomolecule | Mechanism | Biological effect | Refs. |
|---|---|---|---|---|
Gastric cancer | miRNA-522 | Inhibition of cancer cells ferroptosis by targeting ALOX15 and lipid-ROS accumulation | Decreased chemo-sensitivity | |
Head and neck cancer | miRNA-196a | Bind to CDKN1B and ING5 | Acquire cisplatin resistance | Qin et al. (2019) |
Colorectal cancer | lncRNA H19 | Active β-catenin pathway by sponging tumor-inhibitory miR-141 | Promote tumor stemness and drug resistance | |
Colorectal cancer | circSLC7A6 | Mediate miRNAs to regulate the pro-tumor effect of CXCL5 | Promote tumorigenesis | Gu et al. (2020) |
Hepatocellular cancer | Gremlin-1 | By regulating Wnt/β-catenin and BMP signaling | Promote tumor progression and decrease the sensitivity to sorafenib | Qin et al. (2022) |
Pancreatic cancer | miRNA-320a | By mediating PTEN/PI3Kγ signaling | Facilitate the M2 polarization of TAMs | Zhao et al. (2022) |
Breast cancer | miRNA-92 | Increase PD-L1 expression to impair the functions of T cells | Suppress the functions of anti-tumor immune cells | Dou et al. (2020) |
Lung cancer | THBS2 | Inhibit T cell proliferation | Decrease immune cells infiltrations | Yang et al. (2022) |
Esophageal squamous cell cancer | miRNA-21 | IL-6 and miRNA-21 activate the STAT3 signaling to induce M-MDSCs generation | Promote tumor resistance to cisplatin | Zhao et al. (2021) |
Colorectal cancer | LINC00659 | Directly interact with miRNA342-3p to increase ANXA2 expression in cancer cells | Promote tumor progression | Zhou et al. (2021) |
Breast cancer | circHIF1A | Sponge miRNA-580-5p to modulate the expression of CD44 | Promote tumor cell stemness | Zhan et al. (2021) |
Ovarian cancer | TGFβ1 | Activate the SMAD signaling pathway | Promote EMT process | Li et al. (2017) |
Cervical cancer | miRNA-1323 | Target PABPN1 to regulate Wnt/GSK-3β/β-catenin pathway | Promote tumor progression and radio-resistance | Fang et al. (2022) |
Prostate cancer | miRNA-1290 | Inhibit GSK3β/β-catenin signaling pathway | Facilitate tumor growth and metastasis | |
Oral squamous cell cancer | miRNA-34a-5p | Reduced miR-34a-5p up-regulate AXL and activate AKT/GSK-3β/β-catenin signaling pathway | Promote EMT process and cancer metastasis | Li et al. (2018) |
Gastric cancer | circ_0088330 | Sponge miR-1305 to regulate JAK/STAT signaling pathway | Promote tumor progression | Shi et al. (2021) |
Colorectal cancer | circN4BP2L2 | Up-regulate ELF4A3 to regulate PI3K/AKT/mTOR axis | Promote CRC chemoresistance and stemness | Qu et al. (2022) |
Bladder cancer | miRNA-148b-3p | Target PTEN and activate Wnt/β-catenin signaling pathway | Promote EMT process and metastasis | Shan et al. (2021) |
Laryngeal cancer | miRNA-34c-5p | Loss of miR-34c-5p promote the cancer cells malignant phenotypes | Promotion of stem-like phenotypes of cancer cells | |
Breast cancer | SNHG3 | Sponge miR-330-5p to regulate the expression of PKM and inhibit mitochondrial oxidative phosphorylation and increase glycolysis carboxylation | Promote tumor progression | Li et al. (2020) |